ELI LILLY AND COMPANY Patent applications |
Patent application number | Title | Published |
20160115189 | PARASITICIDAL COMPOUNDS, METHODS, AND FORMULATIONS - Provided are compounds of formula I useful for controlling parasites both in animals and agriculture. Further provided are methods for controlling parasite infestations of an animal by administering an effective amount of a compound as described above, or a pharmaceutically acceptable salt thereof, to an animal, as well as formulations for controlling parasite infestations using the compounds described above or an acceptable salt thereof, and an acceptable carrier. | 04-28-2016 |
20160001004 | DELAY MECHANISM SUITABLE FOR COMPACT AUTOMATIC INJECTION DEVICE - A delay mechanism for an automatic injection device having a housing and a medication filled syringe. The delay mechanism includes a shuttle, a follower, a damping compound, at least one biasing member, and a biased plunger element. When moved in the device housing from a first location to a second location, the biased plunger element is adapted to drive the syringe piston within syringe barrel to force medication through the syringe needle for an injection. The follower, when the plunger element is so moved, is freed to move, under urging of the at least one biasing member, from a first position on the housing toward a second position to thereby move the shuttle for retracting the syringe needle into the housing after injection. The damping compound dampens or slows rotation of the follower as the follower moves from the first position toward the second position. | 01-07-2016 |
20150368240 | DIHYDROPYRIDO PYRIMIDINE COMPOUNDS AS AUTOTAXIN INHIBITORS - The present invention provides compounds of the formula (I) or a pharmaceutically acceptable salt thereof. Compounds of the invention are autotaxin inhibitors useful in the treatment of pain associated with osteoarthritis. | 12-24-2015 |
20150353581 | 1-HYDROXY-BENZOOXABOROLES AS ANTIPARASITIC AGENTS - Provided are compounds useful for controlling endoparasites both in animals and agriculture. Further provided are methods for controlling endoparasite infestations of an animal by administering an effective amount of a compound as described above, or a pharmaceutically acceptable salt thereof, to an animal, as well as formulations for controlling endoparasite infestations using the compounds described above or an acceptable salt thereof, and an acceptable carrier. The claimed compounds are described by the following Markush formula: A typical example for a compound according to above formula is: A typical example for a compound according to above formula is: | 12-10-2015 |
20150297681 | Pegylated Insulin Lispro Compounds - The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses. | 10-22-2015 |
20150259415 | CGRP ANTIBODIES - The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain. | 09-17-2015 |
20150203471 | METHODS FOR IMPROVING CHICKEN PRODUCTION - The invention provided methods of improving the growth performance of and/or increasing the meat obtainable from chicken, and/or reducing gas emissions from a chicken or chicken raising operation, comprising administering to the chicken an effective amount of Compound 5 or a physiologically acceptable salt thereof. Also included in the invention are oral chicken feed compositions comprising an effective amount of the above compound, and the crystalline hemifumarate anhydrous salt Form II of the above compound. | 07-23-2015 |
20150152158 | METHODS TO RESTORE GLYCEMIC CONTROL - Provided herein are methods and compositions to achieve a sustained delay in the progression of, or an amelioration of diabetes in a subject, or a delay in diabetes onset in a subject at risk for diabetes, comprising an abbreviated course of administration of a pharmaceutical composition comprising an exendin or an exendin agonist analog in an amount effective to induce β cell regeneration. | 06-04-2015 |
20150150665 | TRANSDERMAL DISPENSING APPARATUS AND METHODS - An applicator for dispensing a therapeutic agent to an animal comprising a housing including first and second sections coupled together, the first and second sections defining a channel therebetween that includes at least one outlet; a hub integral with the first section and extending therefrom, the hub defining a conduit; and a bent path connecting the conduit to the channel. In accordance with this embodiment, the conduit, the bent path and the channel are fluidly connected. | 06-04-2015 |
20150148358 | NOVEL DGAT2 INHIBITORS - The present invention provides compounds of the Formula below: | 05-28-2015 |
20150141335 | THERAPEUTIC USES OF FIBROBLAST GROWTH FACTOR 21 PROTEINS - The present invention relates to therapeutic uses of human fibroblast growth factor 21 (FGF21) proteins. | 05-21-2015 |
20150133562 | Atomoxetine Solution - The present invention provides a novel palatable pharmaceutical composition in the form of aqueous solution of atomoxetine. The oral aqueous solution of this invention will significantly reduce the potently bitter taste of atomoxetine, and further avoid swallow issue for young and elderly patients. | 05-14-2015 |
20150010573 | IL-17 ANTIBODY FORMULATION - The present invention provides stabilized pharmaceutical formulations for anti-IL-17 antibodies, comprising e.g. citrate, sodium chloride and polysorbate-80 at pH 5.7. These stabilized anti-IL-17 antibody pharmaceutical formulations can be used to treat rheumatoid arthritis, psoriasis, ankylosing spondilitis, psoriatic arthritis or multiple myeloma. | 01-08-2015 |
20140371269 | PHENYL METHANESULFONAMIDE DERIVATIVES USEFUL AS MGAT-2 INHIBITORS - The present invention provides compounds of Formula I or a pharmaceutical salt thereof, where the variables for R1, R2, and R3 are as described herein; methods of treating a condition such as hypertriglyceridemia; and processes for preparing the compounds. | 12-18-2014 |
20140357664 | 3,4-DIHYDROISOQUINOLIN-2(1H)-YL COMPOUNDS - The invention provides certain 3,4-dihydroisoquinolin-2(1H)-yl compounds, particularly compounds of formula I, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat cognitive impairment associated with Parkinson's disease or schizophrenia. | 12-04-2014 |
20140349310 | Anti-c-Met Antibodies - Provided is a monoclonal antibody, or antigen-binding fragment thereof that binds to c-Met. Such antibodies, or antigen-binding fragments thereof, are useful in in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting cell surface c-Met receptor levels for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients harboring tumors in which c-Met is implicated in pathogenesis. | 11-27-2014 |
20140324021 | MEDICINAL PATCH AND INJECTOR SYSTEM - An injection system including a wearable component (e.g., a patch) adapted to be worn by a user, and a medication delivery component (e.g., injection device) configured to cooperate with the wearable component to deliver medication to the user. The wearable component can provide a target area to the user for targeting the medication delivery component during use, and further serve to prepare the injection site to minimize the potential for injection site reactions. Both the wearable component and the medication delivery component can include electronics and/or other devices for detecting and/or communication information regarding usage of the injection system including dose amount, frequency, time, etc. The system can be configured to communicate such information to a third party, such as a health care professional. | 10-30-2014 |
20140309251 | SPIROTHIENOPYRAN-PIPERIDINE DERIVATIVES AS ORL-1 RECEPTOR ANTAGONISTS FOR THEIR USE IN THE TREATMENT OF ALCOHOL DEPENDENCE AND ABUSE - The use of ORL-1 receptor antagonists of the formula: | 10-16-2014 |
20140296782 | INJECTION DEVICES WITH ERGONOMIC ENHANCEMENTS - Injection devices with ergonomic enhancements are disclosed. Generally, the injection devices include large oversized grips, including flanges at the base end of the device for enhanced stability. Push-type and squeeze-type devices are described, as well as manual injectors and auto-injectors. Such injection devices are useful for delivering a fluid (e.g. medication) to a patient. | 10-02-2014 |
20140275121 | CDC7 Inhibitors - The present invention provides isoindolinone compounds, or a pharmaceutically acceptable salt thereof, that inhibit CDC7 and, therefore may be useful in treating cancer. | 09-18-2014 |
20140275044 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS - The present invention provides a compound of Formula I: | 09-18-2014 |
20140275002 | AZETIDINYLOXYPHENYLPYRROLIDINE COMPOUNDS - The invention provides certain azetidinyloxyphenylpyrrolidine compounds, particularly compounds of formula I wherein R is hydrogen or methyl, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat overactive bladder. | 09-18-2014 |
20140271675 | THERAPEUTIC USES FOR VEGFR1 ANTIBODIES - The present invention relates to methods of using VEGFR1 antibodies for the treatment of chronic kidney disease. | 09-18-2014 |
20140271671 | RANDOM HOMOZYGOUS GENE PERTURBATION (RHGP) WITH THERMAL ASSYMETRIC INTERLACED (TAIL)-PCR - A method for identifying host genes and encoded proteins for potential targets for therapeutic intervention employs a Gene Search Vector that is either lentivirus or MMLV-based, and can be used to interrogate an entire cell genome without prior knowledge of the genomic sequence. This Random Homozygous Gene Perturbation (RUGP) technique is rapidly verifiable and is used to identify potential host targets for intervention for influenza, HIV and other viral infections. Using Thermal Assymetric Interlaced (TAIL)-PCR, the period for identification of promising targets is reduced from months to weeks or less. Specific targets including PTCH1, Robo1 and Nedd4 are reviewed in detail. | 09-18-2014 |
20140271647 | Pan-ELR+ CXC CHEMOKINE ANTIBODIES - Antibodies are provided that specifically bind seven human ELR | 09-18-2014 |
20140256933 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS - The present invention provides compounds of Formula I: | 09-11-2014 |
20140255422 | ANTIBODIES THAT BIND TO IL-23 - The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer. | 09-11-2014 |
20140255406 | ANTI-TNF-ANTI-IL-17 BISPECIFIC ANTIBODIES - Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNFα) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS). | 09-11-2014 |
20140236084 | Automatic Injection Device With Delay Mechanism Including Dual Functioning Biasing Member - An automatic injection apparatus including a delay mechanism for properly delivering medication prior to the needled syringe of the apparatus being retracted. In one form, the delay mechanism includes a shuttle for the syringe, a follower, a locking member, a damping compound between the follower and a supporting surface to dampen rotation of the follower relative to the shuttle, and a dual functioning biasing member acting between the shuttle and the follower. When the locking member moves to a release position during an injection, the dual functioning biasing member first provides a torsional force to force the follower to rotate relative to the shuttle from a latching position to an unlatching position, and then the dual functioning biasing member provides an axial force to force the shuttle axially relative to the follower to move the shuttle for retracting the syringe needle into the housing of the apparatus after injection. | 08-21-2014 |
20140235718 | PHENOXYETHOXY COMPOUNDS - The present invention provides a compound of the Formula I: | 08-21-2014 |
20140235621 | HEMATOPOIETIC NEOPLASM CHEMOTHERAPY - A method and medicament for treating mixed lineage leukemia; translocated mixed lineage leukemia; translocated mixed lineage leukemia based acute myelogenous leukemia; translocated mixed lineage leukemia based acute lymphoid leukemia; a non-MLL based chronic myeloproliferative disorder, or non-MLL based acute lymphoid leukemia is provided. | 08-21-2014 |
20140206877 | NOVEL INTERMEDIATE AND PROCESS USEFUL IN THE PREPARATION OF -(2-CHLOROPHENYL)-METHANONE - The present invention relates to novel compounds, (2-chlorophenyl)-[2-(2-hydroxy-2-pyridin-4-yl-vinyl)pyridin-3-yl]methanone benzoate, and (2-chlorophenyl)-[2-(2-hydroxy-2-pyridin-4-yl-vinyl)pyridin-3-yl]methanone toluate, which are useful intermediates for the preparation of the compound of Formula I: | 07-24-2014 |
20140206613 | METHODS TO RESTORE GLYCEMIC CONTROL - Provided herein are methods and compositions to achieve a sustained delay in the progression of, or an amelioration of diabetes in a subject, or a delay in diabetes onset in a subject at risk for diabetes, comprising an abbreviated course of administration of a pharmaceutical composition comprising an exendin or an exendin agonist analog in an amount effective to induce β cell regeneration. | 07-24-2014 |
20140200231 | Bicyclic Pyrimidine Compounds - The present invention provides compounds of the Formula I: | 07-17-2014 |
20140180244 | LOCKING ASSEMBLY FOR PREVENTING DISPENSING OF DOSE FROM MEDICATION DISPENSING DEVICE - A locking assembly for a medication dispensing device including a housing, a drive member, a medication cartridge having a barrel holding medication between a movable plunger and a septum, and a dose delivery mechanism for controlling the advancement of the drive member. The locking assembly, in one form, includes a lock member, biased to move from a first position to a second position, with a first actuating element. The locking assembly also includes a second actuating element disposed on the drive member and cooperatively configured with the first actuating element. If the drive member of the device moves rearward from the shipped position due to a freezing of the medication, the second actuating element engages the first actuating element such that the lock member moves from the first position to the second position to lock the medication dispensing device from further dose dispensing. | 06-26-2014 |
20140180218 | REFILL MODULE FOR AN INJECTION DEVICE - A refill module for use with a plunger assembly and having a housing ( | 06-26-2014 |
20140171497 | ANIMAL SUPPLEMENTS AND COMPOSITIONS CONTAINING SOLUABLE MONENSIN AND METHODS THEREFOR - The present disclosure provides animal feed supplements comprising a therapeutically effective amount of monensin and a solvent, wherein the supplement is a solution. The disclosure also provides food compositions comprising a therapeutically effective amount of monensin, a solvent, and an animal feed, methods of administering the food compositions, and processes for making the food compositions. | 06-19-2014 |
20140170161 | BMP-6 Antibodies - The present invention relates to antibodies, or antigen-binding fragments thereof, that bind to human BMP-6, compositions comprising such antibodies, or antigen-binding fragments thereof, and methods of using the same for treatment of anemia of chronic disease. | 06-19-2014 |
20140163097 | ANIMAL SUPPLEMENTS AND FOOD COMPOSITIONS CONTAINING SOLUBLE MONENSIN COMPOSITION, AND METHODS AND PROCESSES THEREFOR - The present disclosure provides animal feed supplements comprising a therapeutically effective amount of monensin, a solvent, and a mineral mix, wherein the mineral mix is substantially free of monocalcium phosphate. In addition, the present disclosure provides processes of preparing animal feed supplements and animal food compositions comprising such animal feed supplements. The present disclosure provides animal feed supplements comprising a therapeutically effective amount of monensin, a solvent, and an alkaline component. In addition, the present disclosure provides animal food compositions containing such animal feed supplements, and methods for their use. | 06-12-2014 |
20140162967 | NOVEL PYRAZOLE COMPOUNDS - The present invention provides a compound of Formula II: | 06-12-2014 |
20140148441 | 6-((S)-1--ETHYL)-3H-1,3-BENZOTHIAZOL-2-ONE AS A TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONIST - A TARP γ8 dependant AMPA receptor antagonist of the formula: | 05-29-2014 |
20140142544 | MEDICATION INJECTOR APPARATUS WITH DRIVE ASSEMBLY THAT FACILITATES RESET - A medication injector apparatus such as an injection pen. The injection pen includes a resettable, cartridge plunger drive assembly including an axially floating nut, a cartridge plunger engaging screw, and a drive clutch movable with the nut and which when rotated causes the screw to screw through the nut. When a cartridge assembly is mounted to the pen base, the floating nut and drive clutch are shifted proximally such that the drive clutch is in torque transmitting engagement with a rotatable drive member of the pen, such that rotation of that drive member results in drive screw advancement through the nut in the distal direction. When the cartridge assembly is not mounted to the pen base, the floating nut and drive clutch are biased distally to disengage the drive clutch from torque transmitting engagement with the rotatable drive member and to thereby allow the drive screw to be reset proximally through the nut to a position more retracted within the pen base. The injection pen also may include an injection clicker assembly having a collar arranged coaxially on a drive sleeve and which oscillates axially on the drive sleeve that rotates during medication dispensing to provide an audible clicking sound that indicates injecting use of the pen. The injection pen also may include a doseable quantity identifier that uses a rotational matrix and a sensor for electrically sensing the arrangement of the dose setting mechanism of the pen, which identifier may be part of a therapeutic dose indicating system that utilizes a cartridge recognizer to recognize a concentration of medication so as to allow an automatic determination of a therapeutic dose. The injection pen further may include an assembly for selectively rotating a drive sleeve of the pen, which assembly has a dial that rotates out during dose setting and which translates in without rotation during dose injecting. | 05-22-2014 |
20140135280 | ECTOPARASITICIDAL METHODS AND FORMULATIONS - Provided are novel methods and formulations for topically controlling ectoparasite infestations in animals using spinetoram, or a pharmaceutically acceptable salt thereof. | 05-15-2014 |
20140121199 | (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS - A dual H1/5-HT | 05-01-2014 |
20140113944 | BICYCLO (3.1.0) HEXANE-2, 6-DICARBOXYLIC ACID DERIVATIVES AS MGLU2 RECEPTOR AGONIST - The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, and generalized anxiety disorder. | 04-24-2014 |
20140107149 | PARASITICIDAL DIHYDROISOXAZOLE COMPOUNDS - Provided are dihydroisoxazole compounds I useful for controlling parasites both in animals and agriculture. Further provided are methods for controlling parasite infestations of an animal by administering an effective amount of a compound as described above, or a pharmaceutically acceptable salt thereof, to an animal, as well as formulations for controlling parasite infestations using the compounds described above or an acceptable salt thereof, and an acceptable carrier. Also provided are compounds and processes useful for making the dihydroisoxazole compounds. | 04-17-2014 |
20140100179 | NOVEL UREA COMPOUNDS - The present invention provides a compound of Formula I: | 04-10-2014 |
20140094491 | DIMETHYL-BENZOIC ACID COMPOUNDS - The present invention provides a compound of the Formula II: | 04-03-2014 |
20140094454 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS - The present invention provides compounds of Formula I: | 04-03-2014 |
20140065138 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF - The present invention provides anti-N3pGlu Aβ antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the anti-N3pGlu Aβ antibodies or antigen-binding fragment thereof for the treatment of Alzheimer's disease. | 03-06-2014 |
20140056893 | Homodimeric Proteins - This present invention relates to a homodimeric protein comprising fibroblast growth factor 21 (FGF21) and glucagon-like peptide (GLP-1), pharmaceutical compositions comprising the homodimeric protein, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such homodimeric protein. | 02-27-2014 |
20140024586 | USE OF AN FGF-21 COMPOUND AND A GLP-1 COMPOUND FOR THE TREATMENT OF OBESITY - The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP- | 01-23-2014 |
20130330336 | FIBROBLAST GROWTH FACTOR 21 PROTEINS - This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins. | 12-12-2013 |
20130324474 | VARIANTS OF HUMAN GDNF - The present invention relates to novel variants of human glial cell-derived neurotrophic factor (GDNF) and methods for their use. | 12-05-2013 |
20130324460 | FIBROBLAST GROWTH FACTOR 21 VARIANTS - This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants. | 12-05-2013 |
20130303471 | NOVEL PYRAZOLE COMPOUNDS - The present invention provides a compound of Formula II: | 11-14-2013 |
20130280294 | BOVINE VIRAL DIARRHEA VIRUS TYPE 1B VACCINE COMPOSITIONS AND METHODS - Disclosed are immunogenic compositions, and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular, the invention provides immunogenic compositions and methods for preventing, treating, managing, and/or ameliorating a viral or microbial infection, or one or more symptoms thereof, including, for example, those infections giving rise to shipping fever, bovine respiratory disease complex, and/or bovine viral diarrhea, particularly in susceptible or infected animals. | 10-24-2013 |
20130280256 | ANTI-BAFF-ANTI-IL-17 BISPECIFIC ANTIBODIES - Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM). | 10-24-2013 |
20130266934 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND DIFFERENTIATING VIRAL COMPONENTS OF MULTIVALENT SHIPPING FEVER VACCINES - Disclosed are methods and compositions for identifying viral-specific polynucleotide sequences in a biological sample, and particularly in samples of veterinary origin. Also disclosed are oligonucleotide primer pairs, as well as labeled oligonucleotide detection probes useful in detecting the presence of one or more particular species, strains, types, or subtypes of one or more mammalian pathogens of viral origin, as well as systems, diagnostic kits and articles of manufacture comprising virus-specific primers and labeled detection probes, including those useful in identifying viral components of a multivalent vaccine, and quantitating the potency of particular attenuated, live viruses that comprise a livestock vaccine. In certain embodiments, real-time, quantitative PCR methods have been utilized to identify and distinguish between the three known genetic subtypes of bovine viral diarrhea viruses (BVDV-1a, BVDV-1b, and BVDV-2) in a multivalent bovid shipping fever vaccine. | 10-10-2013 |
20130261111 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS - The present invention provides compounds of Formula I: | 10-03-2013 |
20130252977 | Raf Inhibitor Compounds - The present invention provides a pyrido[2,3-d]pyrimidine compound, or a pharmaceutically acceptable salt thereof, that inhibits Raf and, therefore, may be useful in treating cancer. | 09-26-2013 |
20130237573 | 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS - A mGlu2/3 receptor antagonist of the formula: | 09-12-2013 |
20130237562 | PI3 KINASE/mTOR DUAL INHIBITOR - The present invention provides an imidazo[4,5-c]quinolin-2-one compound, or a pharmaceutically acceptable salt thereof, that inhibits both PI3K and mTOR and, therefore, is useful in the treatment of cancer. | 09-12-2013 |
20130225679 | ANALGESIC COMPOUNDS, METHODS, AND FORMULATIONS - Provided are analgesic compounds, and salts thereof, of formula: (I) wherein A is: (A) Additionally, pharmaceutical formulations and methods of use employing the above compounds are provided. | 08-29-2013 |
20130225602 | 3-SUBSTITUTED-6-(PYRIDINYLMETHOXY)-PYRROLOPYRIDINE COMPOUNDS - The invention provides certain 3-substituted-6-(pyridinylmethoxy)-pyrrolopyridine compounds, particularly compounds of formula I and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat Parkinsons disease Formula (I). | 08-29-2013 |
20130217762 | Selective Androgen Receptor Modulators - The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof. | 08-22-2013 |
20130217699 | PARASITICIDAL DIHYDROISOXAZOLE COMPOUNDS - Provided are dihydroisoxazole compounds I useful for controlling parasites both in animals and agriculture. Further provided are methods for controlling parasite infestations of an animal by administering an effective amount of a compound as described above, or a pharmaceutically acceptable salt thereof, to an animal, as well as formulations for controlling parasite infestations using the compounds described above or an acceptable salt thereof, and an acceptable carrier. Also provided are compounds and processes useful for making the dihydroisoxazole compounds. | 08-22-2013 |
20130210755 | METHODS FOR INHIBITING INSECT INFESTATIONS - Provided are 3 methods and formulations using feed-through administration and dosing of spinosyns for controlling biting or nuisance insects on animals, for controlling equine feces-dependent insects, and for preventing internal infestation of bot larvae in equine animals. | 08-15-2013 |
20130197039 | Novel Benzyl Sulfonamide Derivatives Useful As MOGAT-2 Inhibitors - The present invention provides compounds of Formula below: | 08-01-2013 |
20130190262 | Compounds Useful for Inhibiting Chk1 - The present invention provides an aminopyrazole compound, or a pharmaceutically acceptable salt thereof, that inhibits Chk1 and is useful in the treatment of cancer. | 07-25-2013 |
20130184653 | GEARING MECHANISM FOR A DOSE DELIVERY DEVICE - The invention relates to a gearing mechanism for a dose delivery device wherein the dose can be set by rotating a dose setting member ( | 07-18-2013 |
20130164304 | ANTI-HEPCIDIN ANTIBODIES AND USES THEREOF - Monoclonal antibodies are provided that selectively bind human hepcidin-25 and are characterized as having high affinity for human hepcidin-25 and strong human mature hepcidin neutralizing properties. The antibodies of the invention are useful therapeutically for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment and diagnosis of mature hepcidin-promoted disorders such as anemia, in a human subject. | 06-27-2013 |
20130142806 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF - The present invention provides anti-N3pGlu Aβ antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the anti-N3pGlu Aβ antibodies or antigen-binding fragment thereof for the treatment of Alzheimers disease. | 06-06-2013 |
20130131017 | BORON-CONTAINING SMALL MOLECULES - This invention provides novel compounds, methods of using the compounds, and pharmaceutical compositions containing the compounds. | 05-23-2013 |
20130131016 | BORON-CONTAINING SMALL MOLECULES - This invention provides novel compounds, methods of using the compounds, and pharmaceutical formulations comprising the compounds. | 05-23-2013 |
20130122013 | ANTI-FERROPORTIN 1 MONOCLONAL ANTIBODIES AND USES THEREOF - Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the level of serum iron, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a subject in vivo. | 05-16-2013 |
20130085098 | FIBROBLAST GROWTH FACTOR 21 VARIANTS - This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants. | 04-04-2013 |
20130072658 | PROCESS FOR SOLUBILIZING GLUCAGON-LIKE PEPTIDE 1 COMPOUNDS - Disclosed is a method of preparing a GLP-1 compound that is soluble in aqueous solution at pH 7.4 from a GLP-1 compound that is substantially insoluble in aqueous solution at pH 7.4. The insoluble GLP-1 compound is dissolved in aqueous base or in aqueous acid to form a GLP-1 solution. The GLP-1 solution is then neutralized to a pH at which substantially no amino acid racemization of the GLP-1 compounds occurs, after which the soluble GLP-1 compound is isolated from the neutralized solution. | 03-21-2013 |
20130071405 | ANTIBODIES TO PCSK9 AND USES THEREOF - The present invention relates to antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9), or antigen-binding fragments thereof, compositions comprising such PCSK9 antibodies or antigen-binding fragments, and methods of using the same for the treatment of hyperlipidemia or hypercholesterolemia. | 03-21-2013 |
20130045990 | NOVEL 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVE USEFUL FOR THE TREATMENT OF DIABETES - The present invention provides a compound of the formula below | 02-21-2013 |
20130039996 | POTENTIATION OF CANCER CHEMOTHERAPY BY 7-(2, 5- DIHYDRO- 4-IMIDAZO [1, 2-A] PYRIDINE-3-YL-2,5-DIOXO-IH-PYRROL-3-YL)-9-FLUORO-1,2,3,4 TETRAHYDRO -2-(1-PIPERIDINYL-CARBONYL)-PYRROLO [3,2,1-JK] [1,4] BENZODIAZEPINE - An improved method for treating gastric cancer, ovarian cancer, non-small cell lung cancer, or colorectal cancer in a patient is described, as well as pharmaceutical compositions useful for the method and a process for preparing said compositions. | 02-14-2013 |
20130029972 | NOTCH PATHWAY SIGNALING INHIBITOR COMPOUND - The present invention provides a compound, or a pharmaceutically acceptable salt or hydrate, and a pharmaceutical composition containing said compound, or a pharmaceutically acceptable salt or hydrate, useful as a Notch pathway signaling inhibitor for the treatment of cancer. | 01-31-2013 |
20130023471 | METHODS TO RESTORE GLYCEMIC CONTROL - Provided herein are methods and compositions to achieve a sustained delay in the progression of, or an amelioration of diabetes in a subject, or a delay in diabetes onset in a subject at risk for diabetes, comprising an abbreviated course of administration of a pharmaceutical composition comprising an exendin or an exendin agonist analog in an amount effective to induce cell regeneration. | 01-24-2013 |
20130017995 | MODIFIED ANIMAL ERYTHROPOIETIN POLYPEPTIDES AND THEIR USES - Modified animal erythropoietin polypeptides and uses thereof are provide. | 01-17-2013 |
20120329820 | Pyridinoylpiperidines As 5-HT1F Agonists - The present invention relates to compounds of formula I: | 12-27-2012 |
20120329809 | PURINE COMPOUNDS USED AS CB2 AGONISTS - A compound of the formula (I) and pharmaceutical compositions for the treatment of pain. | 12-27-2012 |
20120323177 | Automatic Injection Device With Delay Mechanism Including Dual Functioning Biasing Member - An automatic injection apparatus including a delay mechanism for properly delivering medication prior to the needled syringe of the apparatus being retracted. In one form, the delay mechanism includes a shuttle ( | 12-20-2012 |
20120323001 | BACE INHIBITORS - The present invention provides BACE inhibitors of Formula I: | 12-20-2012 |
20120322841 | Aldosterone Synthase Inhibitor - The present invention provides aldosterone synthase inhibitors of the formula: | 12-20-2012 |
20120322828 | METHODS FOR CONTROLLING PAIN IN EQUINES USING A TRANSDERMAL SOLUTION OF FENTANYL - This invention provides methods of controlling pain in an equine for an effective period of time comprising transdermally administering a composition comprising fentanyl, a penetration enhancer, and a volatile liquid, wherein the composition is a solution. The invention also provides a single unit dose of the composition. | 12-20-2012 |
20120316174 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS - The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer. | 12-13-2012 |
20120302608 | Novel Imidazole Derivatives Useful for the Treatment of Arthritis - The present invention provides compounds of the formula below: | 11-29-2012 |
20120302547 | NOVEL MCH RECEPTOR ANTAGONISTS - The present invention relates to a melanin concentrating hormone antagonist compound of formula (I) wherein R | 11-29-2012 |
20120264683 | USE OF AN FGF-21 COMPOUND AND A GLP-1 COMPOUND FOR THE TREATMENT OF OBESITY - The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP-1 compound. In addition, the present invention also provides methods to treat obesity by administering an FGF-21 compound in combination with a GLP-1 compound. The present invention also discloses combinations useful in the methods of the present invention. | 10-18-2012 |
20120263723 | c-Met Antibodies - Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met. | 10-18-2012 |
20120258109 | ANTIBODIES THAT BIND TGF-ALPHA AND EPIREGULIN - The present invention provides antibodies that bind human TGF-alpha and human Epiregulin and are characterized as having high affinity, selective, and strong neutralizing properties. The antibodies are useful in the treatment of diabetic nephropathy. | 10-11-2012 |
20120252838 | TETRAHYDROTRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE MGLU5 RECEPTOR POTENTIATORS USEFUL FOR THE TREATMENT OF SCHIZOPHRENIA - The present invention provides certain tetrahydrotriazolopyridine derivatives, pharmaceutical compositions thereof, methods of using the same and processes for preparing the same. Formula (I) wherein R | 10-04-2012 |
20120252746 | Methods for Internally Controlling or Treating Equine BOT Larvae - Provided are novel methods and formulations for orally controlling bot larvae in the gastrointestinal tract of equine animal. | 10-04-2012 |
20120232024 | THERAPEUTIC USES OF SOLUBLE ALPHA-KLOTHO - The present invention relates to therapeutic uses of soluble alpha-Klotho. | 09-13-2012 |
20120220616 | NOVEL SPIROPIPERIDINE COMPOUNDS - A compound of the formula: or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition, and a method for treating diabetes. | 08-30-2012 |
20120214784 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS - An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described. ORL-1 antagonists are deemed to be useful in the treatment of depression and/or the treatment of overweight, obesity, and/or weight maintenance post treatment for overweight or obesity. Certain compounds have also demonstrated through animal models that the compounds of the present invention are useful for the treatment of migraines. | 08-23-2012 |
20120208980 | PROCESS FOR SOLUBILIZING GLUCAGON-LIKE PEPTIDE 1 COMPOUNDS - Disclosed is a method of preparing a GLP-1 compound that is soluble in aqueous solution at pH 7.4 from a GLP-1 compound that is substantially insoluble in aqueous solution at pH 7.4. The insoluble GLP-1 compound is dissolved in aqueous base or in aqueous acid to form a GLP-1 solution. The GLP-1 solution is then neutralized to a pH at which substantially no amino acid racemization of the GLP-1 compounds occurs, after which the soluble GLP-1 compound is isolated from the neutralized solution. | 08-16-2012 |
20120208849 | METHODS FOR CONTROLLING PAIN IN CANINES USING A TRANSDERMAL SOLUTION OF FENTANYL - This invention provides methods of controlling pain in a canine comprising transdermally administering a composition comprising fentanyl, a penetration enhancer, and a volatile liquid, wherein the composition is a solution. The invention also provides a single unit dose of the composition. | 08-16-2012 |
20120202797 | SUBSTITUTED [(5H-PYRROLO[2,1-c][1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLP- ROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS - A dual H1/5-HT | 08-09-2012 |
20120195904 | METHOD TO TREAT USING ANTAGONISTIC ANTI-hTNFSF13B HUMAN ANTIBODIES - Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b (e.g., K | 08-02-2012 |
20120184577 | PI3 KINASE/mTOR DUAL INHIBITOR - The present invention provides an imidazo[4,5-c]quinolin-2-one compound, or a pharmaceutically acceptable salt thereof, that inhibits both PI3K and mTOR and, therefore, is useful in the treatment of cancer. | 07-19-2012 |
20120172422 | Methods of Treatment Using a Prodrug of an Excitatory Amino Acid - This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders. | 07-05-2012 |
20120157506 | Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis - The present invention provides compounds of the formula below | 06-21-2012 |
20120149684 | AKT INHIBITORS - The present invention provides AKT inhibitors of the formula: Formula I The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and method of using compounds of Formula I. | 06-14-2012 |
20120142724 | OXAZOLO[5-4-b]PYRIDIN-5-YL COMPOUNDS - The present invention provides oxazolo[5,4-b]pyridin-5-yl compounds useful in the treatment of cancer. | 06-07-2012 |
20120130313 | NEEDLE CARTRIDGE FOR MEDICATION INJECTION DEVICE - A cartridge with injection needles for an injection device. The cartridge includes a plurality of injection needle assemblies, each including a hub, mounted to be shiftable in cavities of a needle assembly support. A hub ledge having a drive member engageable push surface projects within a gap between a first hub portion and a second hub portion. Driving engagement of the push surface by an injection device drive member shifts the needle assembly from a retracted position to an injection position, during which shifting the second hub portion moves relative to the first hub portion. A pull surface on the second hub portion is engagable with the drive member for lifting the needle assembly from the injection position. | 05-24-2012 |
20120129902 | 4-SUBSTITUTED-3-PHENYLSULFANYLMETHYL-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS - A mGlu2/3 receptor antagonist of the formula: | 05-24-2012 |
20120108947 | METHOD FOR PREDICTING WEIGHT GAIN ASSOCIATED WITH A PHARMACEUTICAL THERAPY - Methods for using TRL V6 as a biomarker for the risk of weight gain associated with treatment of a patient with a pharmaceutical agent, as for example, olanzapine. | 05-03-2012 |
20120095020 | Cathepsin S Inhibitor Compounds - The present invention provides a compound of Formula (I): | 04-19-2012 |
20120083511 | CRYSTALLINE (R)-(E)-2-(4-(2-(5-(1-(3,5-DICHLOROPYRIDIN-4-YL)ETHOXY)-1H-INDAZOL-3-YL)V- INYL)-1H-PYRAZOL-1-YL)ETHANOL - The present invention provides crystalline (R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol useful in the treatment of cancer. | 04-05-2012 |
20120082641 | FORMULATIONS FOR BOVINE GRANULOCYTE COLONY STIMULATING FACTOR AND VARIANTS THEREOF - This invention provides stable aqueous formulations comprising a bG-CSF polypeptide or a variant thereof, a buffer substance, and an excipient, wherein said formulation is substantially free of polyoxyethylene (20) sorbitan monolaurate. The invention also provides methods of using, a lyophilized or powdered form of, and processes for, preparing the formulation. | 04-05-2012 |
20120071490 | P70 S6 KINASE INHIBITORS - The present invention provides p70 S6 kinase inhibitors of the formula: | 03-22-2012 |
20120058990 | Trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-be- nzazepin-1-yl]methyl]-cyclohexanecarboxylic acid - Abstract Compounds of a formula entitled, trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid, as a free acid or a pharmaceutically acceptable salt thereof, hydrate, and hydrate in crystalline form; pharmaceutical formulations; and methods of use are disclosed. | 03-08-2012 |
20120041065 | LAURIC ACID DISTILLATE FOR ANIMAL FEED - Provided are novel methods and formulations for enhancing feed efficiency and reducing mortality in food animals. | 02-16-2012 |
20120028984 | Compound Useful As A c-MET Inhibitor - The present invention relates to a c-Met inhibitor (disclosed herein) or a pharmaceutically acceptable salt thereof useful in treating cancer mediated by activity of c-Met receptors. | 02-02-2012 |
20120028961 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist - The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT | 02-02-2012 |
20120022466 | Apparatus for Injecting a Pharmaceutical with Automatic Syringe Retraction Following Injection - A pharmaceutical delivery apparatus with an automatic syringe retraction following a manually controlled injection. The apparatus includes a housing ( | 01-26-2012 |
20120022140 | Method of treating a cancer with a survivin antisense oligonucleotide and paclitaxel - Provided is a method of treating cancer of the stomach, comprising administering to a patient a therapeutically effective combination of a Survivin antisense oligonucleotide and paclitaxel. | 01-26-2012 |
20110312954 | MINERALOCORTICOID RECEPTOR ANTAGONIST AND METHODS OF USE - The present invention provides a compound of the formula: Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart failure, hypertension, diabetic nephropathy, or chronic kidney disease, comprising administering Compound (I), or a pharmaceutically acceptable salt thereof. | 12-22-2011 |
20110305711 | CGRP ANTIBODIES - The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain. | 12-15-2011 |
20110294792 | PURINE DERIVATIVES AS KINASE INHIBITORS - The present invention provides kinase inhibitors of Formula I. | 12-01-2011 |
20110288032 | ENZASTAURIN FOR THE TREATMENT OF CANCER - The present invention relates to HDAC2 as a biological marker for treating cancer in a patient using Enzastaurin as a single agent or in combination with a Class I selective HDAC inhibitor. | 11-24-2011 |
20110281847 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS - The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause. | 11-17-2011 |
20110269745 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS - The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification. | 11-03-2011 |
20110263602 | TETRASUBSTITUTED PYRIDAZINE HEDGEHOG PATHWAY ANTAGONISTS - The present invention provides novel tetrasubstituted pyridine hedgehog pathway antagonists of the following formula I (I) or a pharmaceutically acceptable salt thereof, wherein: X is C—R | 10-27-2011 |
20110250205 | ANTI-SCLEROSTIN ANTIBODIES - Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject. | 10-13-2011 |
20110237503 | NOVEL PEPTIDES AND METHODS FOR THEIR PREPARATION AND USE - The present invention is in the field of treatment of diabetes and relates to peptides that exhibit activity for both glucose-dependent insulinotropic peptide receptor (GIP-R) and glucagon-like peptide-1 receptor (GLP-1-R) and are selective over glucagon receptor (Gluc-R). Specifically provided are GIP analogs with amino acid substitutions introduced to modulate activity for both GIP-R and GLP-1-R and maintain selectivity over Gluc-R. | 09-29-2011 |
20110212977 | P70 S6 KINASE INHIBITOR AND MTOR INHIBITOR COMBINATION THERAPY - The present invention provides a combination therapy comprising the compound 4-[4-[4-(4-fluoro-3-trifluoromethyl-phenyl)-1-methyl-1H-imidazol-2-yl]-piperidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine, or a pharmaceutically acceptable salt thereof, and an mTOR inhibitor for use in the treatment of glioblastoma multiforme, adenocarcinomas of the colon, non-small-cell lung cancer, small-cell lung cancer, cisplatin-resistant small-cell lung cancer, ovarian cancer, leukemia, pancreatic cancer, prostate cancer, mammary carcinoma, renal cell carcimoma, multiple myeloma, Kaposis Sarcoma, Hodgkins lymphoma, lymphangioleiomyomatosis, Non-Hodgkins lymphoma or sarcoma. | 09-01-2011 |
20110212092 | GLUCAGON RECEPTOR ANTAGONISTS - The present invention relates to glucagon receptor polypeptide antagonists which inhibit the binding of the hormone glucagon to its receptor. More particularly, the present invention relates to high affinity glucagon receptor antibodies or Fab fragments thereof that inhibit binding of glucagon to its receptor and their use in the treatment or prevention of type 2 diabetes (NIDDM) and related disorders in mammalian species. | 09-01-2011 |
20110207752 | P70 S6 KINASE INHIBITOR AND EGFR INHIBITOR COMBINATION THERAPY - The present invention provides a combination therapy comprising the compound 4-[4-[4-(4-fluoro-3-trifluoromethyl-phenyl)-1-methyl-1H-imidazol-2-yl]-piperidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor for use in the treatment of glioblastoma multiforme, adenocarcinomas of the colon, non-small-cell lung cancer, small-cell lung cancer, cisplatin-resistant small-cell lung cancer, ovarian cancer, leukemia, pancreatic cancer, prostate cancer, mammary carcinoma, renal cell carcimoma, multiple myeloma, Kaposis Sarcoma, Hodgkins lymphoma, lymphangioleiomyomatosis, Non-Hodgkins lymphoma or sarcoma. | 08-25-2011 |
20110207721 | PURINE DERIVATIVES AS KINASE INHIBITORS - The present invention provides kinase inhibitors of Formula I. | 08-25-2011 |
20110207672 | METHODS OF TREATMENT USING A PRODRUG OF AN EXCITATORY AMINO ACID - This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders. | 08-25-2011 |
20110207670 | COMPOSITIONS AND METHODS OF USE FOR SOLUBLE THROMBOMODULIN VARIANTS - The present invention provides a method for preventing and/or treating a patient with acute kidney injury caused by a variety of conditions. The method comprises administering to the patient soluble thrombomodulin variants that do not bind thrombin. In conjunction with standard of care, soluble thrombomodulin variants that do not bind thrombin will prevent or reduce acute kidney injury and subsequent morbidity and mortality. | 08-25-2011 |
20110190304 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS - The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer. | 08-04-2011 |
20110189190 | ANTI-HEPCIDIN-25 SELECTIVE ANTIBODIES AND USES THEREOF - Monoclonal antibodies are provided that bind to the N-terminus of human hepcidin-25 and are characterized as having high affinity and selectivity for the polypeptide. The antibodies of the invention are useful for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment of various disorders, such as anemia, in a human subject. The antibodies of the invention are also useful as analytical tools, such as in sandwich ELISA. | 08-04-2011 |
20110178093 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS - The present invention provides novel tetrasubstituted pyridazine hedgehog pathway antagonists useful in the treatment of cancer. | 07-21-2011 |
20110166345 | THIAZOLYL-PYRAZOLOPYRIMIDINE COMPOUNDS AS SYNTHETIC INTERMEDIATES AND RELATED SYNTHETIC PROCESSES - The present invention relates to a synthetic intermediate of the formula: | 07-07-2011 |
20110166182 | Selective Estrogen Receptor Modulator for the Treatment of Osteoarthritis - The present invention is directed to a compound of the formula (A): or a pharmaceutically acceptable salt thereof; and also to compounds of formula (I): or a pharmaceutically acceptable salt thereof. | 07-07-2011 |
20110152334 | MGLU2 AGONISTS - The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, depression, and generalized anxiety disorder. | 06-23-2011 |
20110152182 | OXYNTOMODULIN PEPTIDE ANALOGUE - The present invention provides an Oxyntomodulin peptide analogue useful in the treatment of diabetes and/or obesity. | 06-23-2011 |
20110152181 | OXYNTOMODULIN PEPTIDE ANALOGUE - The present invention provides Oxyntomodulin peptide analogues useful in the treatment of diabetes and/or obesity. | 06-23-2011 |
20110150929 | SARS vaccine compositions and methods of making and using them - Described is a composition and method for reducing the occurrence and severity of infectious diseases, especially infectious diseases such as SARS, in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating immunogenic modified, partially delipidated viral particles with reduced infectivity. The present invention provides delipidated viral vaccine compositions, such as therapeutic vaccine compositions, comprising these modified, partially delipidated viral particles with reduced infectivity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism or, in case of a therapeutic vaccine, to treat or alleviate infection against the lipid-containing infections viral organism. The vaccine compositions of the present invention include combination vaccines of modified viral particles obtained from one or more strains of a virus and/or one or more types of virus. | 06-23-2011 |
20110144091 | Inhibitors of Diacylglycerol Acyltransferase - This invention provides compounds of formula I: | 06-16-2011 |
20110124648 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES - The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like. | 05-26-2011 |
20110118326 | Androgen Receptor Modulator and Uses Thereof - The present invention relates to the compound of the formula: | 05-19-2011 |
20110118251 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS - An ORL-1 receptor antagonist of the formula: | 05-19-2011 |
20110105471 | NOVEL CRYSTALLINE COMPOUND AND A PROCESS FOR ITS PREPARATION - A form of crystalline (2S)-2-hydroxy-3-methyl-N-[(1S)-1-methyl-2-oxo-2-[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-butanamide anhydrate Form II having improved flowability and drug-loading properties and a process for its preparation. | 05-05-2011 |
20110105392 | Pegylated Insulin Lispro Compounds - The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses. | 05-05-2011 |
20110092531 | Novel Spiropiperidine Compounds - A compound of the formula: | 04-21-2011 |
20110086027 | ANTI-CXCR4 ANTIBODIES - The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis. | 04-14-2011 |
20110046143 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS - The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer. | 02-24-2011 |
20110039855 | Tetrahydrocyclopenta[b]indole Androgen Receptor Modulators - The present invention provides a compound of the Formula (I), or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating or preventing physiological disorders, particularly reduced bone mass, osteoporosis, osteopenia, reduced muscle mass or strength, or erectile dysfunction comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof. | 02-17-2011 |
20110034511 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS - The present invention relates to compounds of formula I: | 02-10-2011 |
20110034484 | 1,5-DIPHENYL-PYRROLIDIN-2-ONE COMPOUNDS AS CB-1 LIGANDS - CB-1 receptor inverse agonist compounds of Formula (I) and pharmaceutical compositions for the treatment of obesity or cognitive impairment associated with schizophrenia. | 02-10-2011 |
20110034373 | USE OF AN FGF-21 COMPOUND AND A GLP-1 COMPOUND FOR THE TREATMENT OF OBESITY - The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP-1 compound. In addition, the present invention also provides methods to treat obesity by administering an FGF-21 compound in combination with a GLP-1 compound. The present invention also discloses combinations useful in the methods of the present invention. | 02-10-2011 |
20110028520 | 1,5-DIPHENYL-PYRROLIDIN-2-ONE COMPOUNDS AS CB-1 LIGANDS - CB-1 receptor inverse agonist compounds of Formula and pharmaceutical compositions for the treatment of obesity or cognitive impairment associated with schizophrenia. | 02-03-2011 |
20110027290 | ANTI-IL-17 ANTIBODIES - Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful in particular for treating autoimmune, inflammatory, cell proliferative and developmental disorders. | 02-03-2011 |
20110027261 | ANTI-HEPCIDIN ANTIBODIES AND USES THEREOF - Monoclonal antibodies are provided that selectively bind human hepcidin-25 and are characterized as having high affinity for human hepcidin-25 and strong human mature hepcidin neutralizing properties. The antibodies of the invention are useful therapeutically for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment and diagnosis of mature hepcidin-promoted disorders such as anemia, in a human subject. | 02-03-2011 |
20110015199 | GPR119 Agonists - GPR119 agonist compounds of the formula: | 01-20-2011 |
20110009458 | STABLE FORMULATIONS OF THIADIAZOLE DERIVATIVE - The present invention provides formulation parameters and manufacturing conditions for stable pharmaceutical compositions comprising N-{4-(2,2-dimethyl-propionyl)-(5R)-5-[(2-ethylamino-ethanesulfonylamino)-methyl]-5-phenyl-4,5-dihydro-[1,3,4]thiadiazol-2-yl}-2,2-dimethyl-propionamide that minimize undesirable chiral conversion to the less active S enantiomeric form. | 01-13-2011 |
20110009395 | BACE INHIBITORS - The present invention provides BACE inhibitors of Formula I: | 01-13-2011 |
20100331309 | Trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tet- razol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]met- hyl]-cyclohexanecarboxylic acid - Compounds of a formula | 12-30-2010 |
20100324140 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES - The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like. | 12-23-2010 |
20100324048 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS - The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer. | 12-23-2010 |
20100286139 | AMINO PYRAZOLE COMPOUND - The present invention provides amino pyrazole compounds useful in the treatment of chronic myeloproliferative disorders and various cancers, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias. | 11-11-2010 |
20100280062 | (E)-N--METHANESULFONAMIDE AS GLUCOCORTICOID RECEPTOR MODULATOR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS - The present invention provides Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and discloses methods for the treatment of inflammatory and immune disorders comprising administering to a patient in need thereof an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof. | 11-04-2010 |
20100272735 | METHOD TO TREAT USING ANTAGONISTIC ANTI-hTNFSF13B HUMAN ANTIBODIES - Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b (e.g., K | 10-28-2010 |
20100261762 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR - A serotonin and norepinephrine reuptake inhibitor of the formula: | 10-14-2010 |
20100261712 | HEMATOPOIETIC NEOPLASM CHEMOTHERAPY - A method and medicament for treating mixed lineage leukemia; translocated mixed lineage leukemia; translocated mixed lineage leukemia based acute myelogenous leukemia; translocated mixed lineage leukemia based acute lymphoid leukemia; a non-MLL based chronic myeloproliferative disorder, or non-MLL based acute lymphoid leukemia is provided. | 10-14-2010 |
20100260754 | DKK-1 ANTIBODIES - The invention provides human engineered antibodies, antigen-binding fragments thereof, that bind to, and inhibit the activity of, human DKK-1, and which are effective in treating diseases in which pathogenesis is mediated by DKK-1. | 10-14-2010 |
20100249075 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS - The present invention relates to novel tetralin ER-β agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-β mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory bowel disease, and arthritis. | 09-30-2010 |
20100221263 | Anti-Sclerostin Antibodies - Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject. | 09-02-2010 |
20100215698 | METHOD OF TREATING CANCER CELLS TO CREATE A MODIFIED CANCER CELL THAT PROVOKES AN IMMUNOGENIC RESPONSE - The present invention relates to a delipidation method employing a solvent system useful for extracting lipids from cancer cells, thereby creating a modified cancer cell particle. Upon delipidation of the cancer cells, a portion of the cancer cell antigens remain intact. These exposed antigens, or epitopes, foster and promote antibody production. The resulting modified cancer cell particle, or portions of the cancer cell, initiate a positive immunogenic response when administered to an animal or human and help to treat, prevent or delay the onset of cancer. The present invention provides autologous and heterologous vaccine compositions comprising the modified cancer cell with a pharmaceutically acceptable carrier. The present invention provides method of administering these vaccines to treat, prevent or delay the onset of cancer. | 08-26-2010 |
20100210583 | NOVEL ANTIFOLATE COMBINATION THERAPIES - A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent. | 08-19-2010 |
20100197660 | AZEPINE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS - Compounds of formula (I), pharmaceutical compositions comprising them, and methods for their use are described. | 08-05-2010 |
20100197620 | PESTICIDAL FORMULATIONS - The present invention relates to an active composition for controlling or eradicating Phthiraptera, Siphonaptera and Acarina Pests, typically in domestic animals, comprising a synergistic combination of at least one A83543 compound and at least one macrocyclic lactone. The invention also relates to the use of the active composition in pesticidal formulations, the formulations themselves and to the various applications of those formulations as pesticides, specifically in controlling all species of Phthiraptera, Siphonaptera and Acarina pests, typically in domestic animals. Such applications include the control of such external Phthiraptera, Siphonaptera and Acarina pests in domestic animals including but not limited to sheep, cattle, poultry, pigs, goats, camelids, horses, dogs and cats. | 08-05-2010 |
20100184764 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 - The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia. | 07-22-2010 |
20100173857 | Spinosyns For Wound Healing - A spinosyn or a physiologically acceptable derivative or salt thereof for promoting or accelerating wound healing in humans. | 07-08-2010 |
20100152660 | CARTRIDGE WITH MULTIPLE INJECTION NEEDLES FOR A MEDICATION INJECTION DEVICE - A cartridge ( | 06-17-2010 |
20100152181 | AMINO PYRAZOLE COMPOUND - The present invention provides amino pyrazole compounds useful in the treatment of chronic myeloproliferative disorders and various cancers, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias. | 06-17-2010 |
20100152166 | COMPOUNDS AND METHODS FOR MODULATING FXR - Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia. | 06-17-2010 |
20100136021 | TGF-BETA BINDING ANTIBODIES - The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-β1, TGF-β2, and TGF-β3. The antibodies of the invention are useful for mating cell proliferative disorders in a mammal. | 06-03-2010 |
20100130409 | CYCLIC PEPTIDE CXCR4 ANTAGONISTS - Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection. | 05-27-2010 |
20100120854 | TGF-BETA INHIBITORS - The present invention provides crystalline 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole monohydrate. | 05-13-2010 |
20100120785 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS - The present invention provides selective 5-HT | 05-13-2010 |
20100113579 | PRODRUGS OF EXCITATORY AMINO ACIDS - This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders. | 05-06-2010 |
20100093608 | MODIFIED ANIMAL ERYTHROPOIETIN POLYPEPTIDES AND THEIR USES - Modified animal erythropoietin polypeptides and uses thereof are provide. | 04-15-2010 |
20100087631 | ANTI-MYOSTATIN ANTIBODIES - A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope with high affinity preferentially bind GDF-8 over GDF-11 and may he chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing hone density, or for the treatment of various disorders in mammalian and avian species. | 04-08-2010 |
20100087368 | TREATING ACUTE RENAL FAILURE WITH SOLUBLE THROMBOMODULIN VARIANTS - The present invention provides a method for preventing and/or treating subjects with acute renal failure caused by a variety of conditions. The method comprises administering to the subject soluble thrombomodulin which does not activate Protein C. In conjunction with standard of care, soluble thrombomodulin that does not activate Protein C will prevent or reduce acute kidney injury and subsequent morbidity and mortality. | 04-08-2010 |
20100069425 | GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE - The present invention provides Compound (I): Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and methods for the treatment of inflammatory and immune disorders comprising administering to a patient in need thereof an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof. | 03-18-2010 |
20100049125 | DELAY MECHANISM FOR AUTOMATIC INJECTION DEVICE - A delay mechanism for staging the operation of an automatic injection apparatus ( | 02-25-2010 |
20100035812 | Modified Bovine G-CSF Polypeptides And Their Uses - Modified bovine G-CSF polypeptides and uses thereof are provided. | 02-11-2010 |
20090275613 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 - The present invention discloses novel compounds of Formula I: (I) possessing 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11β-HSD type 1 activity. | 11-05-2009 |
20090240036 | Anti-IL-23 Antibodies - The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind to the p19 subunit of IL-23. These antibodies, or antigen-binding portions thereof, are high affinity, neutralizing antibodies useful for the treatment of autoimmune disease. | 09-24-2009 |
20090238881 | IONOPHORE ANTIBIOTIC FORMULATIONS - The invention relates to an ionophore antibiotic composition capable of diluting with water to a substantially stable dispersed form in all water than present, said composition comprising or including:—at least one ionophore antibiotic (preferably monensin) of a mean particle size of less than 20 microns,—and at least one dispersing agent. A method of preparing the ionophore antibiotic composition is also disclosed. | 09-24-2009 |